Funds and ETFs Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:48:43 2024-05-20 pm EDT 5-day change 1st Jan Change
9.665 USD +0.99% Intraday chart for Amicus Therapeutics, Inc. +7.08% -31.78%
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.57 USD
Average target price
17.3 USD
Spread / Average Target
+80.77%
Consensus
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. Funds and ETFs Amicus Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW